PDE5 inhibitor
Tadalafil
Longer-acting that preserves in corpus cavernosum, prostate/bladder, and pulmonary vascular smooth muscle.
Primary Mechanism of Action
Clinical / Scientific
Tadalafil inhibits with a longer half-life than sildenafil, prolonging -dependent smooth-muscle relaxation wherever and an NO/ signal coexist (penile, lower-urinary-tract, and pulmonary vascular beds).
Pathway Targets
PDE5
Scientific explanation
-hydrolysis inhibition.
NO / cGMP signalling
Scientific explanation
Amplification of nitrergic vasodilation.
Pathway Convergence
Clinical / Scientific
Target → pathway → downstream effect → biological consequence. This is a mechanistic map, not a treatment claim.
Sustained cGMP
Target to downstream effect: NO-stimulated cGMP → PDE5 blockade → Prolonged smooth-muscle relaxation
Mechanistically Relevant Repurposed & Adjunctive Applications
Erectile dysfunction
EstablishedMechanistic rationale
Established labelled indication.
Benign prostatic hyperplasia symptoms (labelled regimens)
EstablishedMechanistic rationale
in lower-urinary-tract smooth muscle is the mechanistic basis of labelled BPH symptom regimens.
Pulmonary arterial hypertension (labelled products)
EstablishedMechanistic rationale
Same mechanism in pulmonary arteries for appropriately labelled PAH products.
Mechanistic Application Matrix
| Biological Target | Mechanism | Potential Relevance | Evidence Level |
|---|---|---|---|
| PDE5 | Inhibition | cGMP / smooth-muscle tone | Established mechanism |
Mechanistic Interaction Considerations
Nitrate co-administration is contraindicated. Additive blood-pressure lowering with antihypertensives and alpha-blockers is expected pharmacology. Alcohol and inhibitors can increase exposure.
In Plain Language
Tadalafil is a longer-lasting version of the same idea as sildenafil: it protects the relaxation signal so blood vessels in -rich tissues stay more relaxed when nitric oxide is present.
Compounds Sharing Pathways
Other library compounds whose structured pathway data overlap this ingredient. Shared pathways are not combination recommendations.
PDE5
NO / cGMP signalling
Mechanistic information is provided for scientific and educational purposes. Discussion of biological pathways or investigational applications does not establish clinical efficacy or constitute individualized medical advice.